Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
Dorr, Anthony D Chopra, Charu Coulter, Tanya I Dempster, John Dziadzio, Magdalena El-Shanawany, Tariq Garcez, Tomaz Gompels, Mark Herriot, Richard Jain, Rashmi
Dorr, Anthony D
Chopra, Charu
Coulter, Tanya I
Dempster, John
Dziadzio, Magdalena
El-Shanawany, Tariq
Garcez, Tomaz
Gompels, Mark
Herriot, Richard
Jain, Rashmi
Citations
Altmetric:
Affiliation
Barts Health NHS Trust; Royal Infirmary of Edinburgh; Belfast Health and Social Care Trust; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Publication date
2022-12-21
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
No abstract available.
Citation
Dorr AD, Chopra C, Coulter TI, Dempster J, Dziadzio M, El-Shanawany T, Garcez T, Gompels M, Herriot R, Jain R, Levi M, Lorenzo L, Makki I, Mapazire E, Murng SHK, Noorani S, Savic S, Steele CL, Symons C, Tarzi M, Yong PFK, Kiani-Alikhan S. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit. Allergy. 2023 May;78(5):1369-1371. doi: 10.1111/all.15620
Type
Article